ArticleFrontiers in chemistry2026
Study on the mechanism of TP53 degradation by SFN ubiquitination affecting locally advanced TC progression.
Article in Frontiers in chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aim: Revealing the molecular mechanism of metastasis of advanced thyroid cancer and transforming it into neoadjuvant targeted therapy, to get a great potential to reduce operative mortality and improve clinical prognosis in locally advanced Thyroid Cancer (TC) patients. Methods: Serological tests were conducted to detect the expression level of natural TF-Ab and the sialacidification level of Thomson friedenreich antibody (TF-Ab) in the population; Analysis of downstream acting proteins after exposure to TF-Ag by IP binding mass spectrometry. Clinical histological immunohistochemistry confirmed the expression of the target protein in locally advanced TC tissues. Results: The expression of natural TF-Ab in tumor patients is lower than that in healthy people, while there was no significant difference in the level of sialacidification among antibodies; IP combined with mass spectrometry showed that SFN was a stable and highly expressed molecular interaction protein after exposure to TF-Ag. Clinical histology verified that SFN was significantly higher expressed in locally advanced TC tissues than in inert TC tissues (T1 stage). Cell biology experiments have demonstrated that SFN expression regulation can significantly affect the biological function of TC cells and change the differentiation ratio of CSCs. Intervention of SFN expression Conclusion: The effect of TP53 degradation by SFN ubiquitination on the differentiation of CSCs is a potential molecular mechanism for the widespread metastasis of locally advanced TC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.